DOCSLIB.ORG

Control of the Pericentrosomal H2O2 Level by Peroxiredoxin I Is Critical for Mitotic Progression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Control of the Pericentrosomal H2O2 Level by Peroxiredoxin I Is Critical for Mitotic Progression Published July 6, 2015 This article has original data in the JCB Data Viewer JCB: Report http://jcb-dataviewer.rupress.org/jcb/browse/10902 Control of the pericentrosomal H2O2 level by peroxiredoxin I is critical for mitotic progression Jung Mi Lim,1 Kyung S. Lee,2 Hyun Ae Woo,1 Dongmin Kang,1 and Sue Goo Rhee3 1Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, South Korea 2Laboratory of Metabolism, National Cancer Institute, Bethesda, MD 20892 3Yonsei Biomedical Research Institute, Yonsei University, Seoul 120-749, South Korea Proteins associated with the centrosome play key roles in mitotic progression in mammalian cells. The activity of Cdk1-op- posing phosphatases at the centrosome must be inhibited during early mitosis to prevent premature dephosphorylation of Cdh1—an activator of the ubiquitin ligase anaphase-promoting complex/cyclosome—and the consequent premature degradation of mitotic activators. In this paper, we show that reversible oxidative inactivation of centrosome-bound protein phosphatases such as Cdc14B by H2O2 is likely responsible for this inhibition. The intracellular concentration of H2O2 increases as the cell cycle progresses. Whereas the centrosome is shielded from H2O2 through its association with the H2O2-eliminating enzyme peroxiredoxin I (PrxI) during interphase, the centrosome-associated PrxI is selectively in- activated through phosphorylation by Cdk1 during early mitosis, thereby exposing the centrosome to H2O2 and facili- Downloaded from tating inactivation of centrosome-bound phosphatases. Dephosphorylation of PrxI by okadaic acid–sensitive phosphatases during late mitosis again shields the centrosome from H2O2 and thereby allows the reactivation of Cdk1-opposing phosphatases at the organelle. Introduction on April 13, 2017 Activation of the Cdk1–cyclin B complex occurs first at the cen- et al., 2009; Mocciaro and Schiebel, 2010; Schmitz et al., 2010; trosome during prophase, and its amplification through multiple Domingo-Sananes et al., 2011). feedback loops involving cyclin B, Cdc25B, Cdc25C, Plk, and A fraction of each of APC/C, Cdc20, Cdh1, and Cdk1-op- Aurora A also occurs at this organelle (Jackman et al., 2003; posing phosphatases (Cdc14B, PP1, and PP2A) is present at the Bonnet et al., 2008; Lindqvist et al., 2009). Successful cell cycle centrosome (Leach et al., 2003; Cho et al., 2005; Peters, 2006; progression requires that many cell cycle regulators—including Wu et al., 2008; Schmitz et al., 2010), as are Cdk1, Cdc25, cyclin cyclins A and B, Plk1, and Aurora A—be degraded in a timely B, Plk1, and Aurora A. At the onset of mitosis, Cdk1–cyclin B manner. Degradation of these regulators by the 26S proteasome activity begins to increase as a result of positive feedback loops results from their ubiquitination by the multisubunit ubiqui- including cyclin B, Cdc25, Plk1, and Aurora A. The low level tin ligase anaphase-promoting complex/cyclosome (APC/C). of incipient Cdk1 activity is likely insufficient to allow the ac- Activation of APC/C occurs at the centrosome and requires cumulation of phosphorylated Cdh1 at the centrosome in the THE JOURNAL OF CELL BIOLOGY Cdc20 or Cdh1 as an activator protein (Peters, 2006; Pesin and absence of concurrent suppression of the activity of Cdk1-op- Orr-Weaver, 2008; van Leuken et al., 2008; Wurzenberger and posing phosphatases, which, together with Cdh1, are enriched Gerlich, 2011). Cdh1 is prevented from interaction with APC/C at this organelle. In the absence of such suppression of centro- when Cdh1 is phosphorylated by Cdks. APC/C–Cdh1 activity somal phosphatase activity, further activation of Cdk1 would thus depends on both Cdks as well as Cdk-opposing phospha- not be expected to occur because of the premature degradation tases. The dual-specificity protein tyrosine phosphatase (PTP), of cyclin B, Plk1, and Aurora A. Cdc14B, and the Ser/Thr phosphatases, PP1 and PP2A, have Here, we find that the centrosomal levels of cyclin B, been proposed to function as Cdk1-opposing enzymes in mam- Plk1, and Aurora A as well as mitotic entry are likely regulated malian cells (Bassermann et al., 2008; Mochida et al., 2009; Wu by the local concentration of H2O2 around the centrosome. We were led into this study by our previous observation that PrxI is inactivated when phosphorylated on Thr90 by purified Cdk1–cy- clin B (Chang et al., 2002). Peroxiredoxins (Prxs) are a major Correspondence to Dongmin Kang: [email protected]; or Sue Goo Rhee: [email protected] class of H2O2-eliminating enzymes (Rhee et al., 2012). Mam- Abbreviations used in this paper: APC/C, anaphase-promoting complex/ cyclosome; DPI, diphenyleneiodonium; MAFP, methyl arachidonyl fluorophos- © 2015 Lim et al. This article is distributed under the terms of an Attribution–Noncommercial– phonate; MEF, mouse embryonic fibroblast; NDGA, nordihydroguaiaretic acid; Share Alike–No Mirror Sites license for the first six months after the publication date (see NEM, N-ethylmaleimide; OA, okadaic acid; PACT, pericentrin-AKAP450 cen- http://www.rupress.org/terms). After six months it is available under a Creative Commons trosomal targeting; pHH3, phosphorylated histone H3; Prx, peroxiredoxin; PTP, License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at protein tyrosine phosphatase; SIM, structured illumination microscopy. http://creativecommons.org/licenses/by-nc-sa/3.0/). Supplemental Material can be found at: /content/suppl/2015/07/06/jcb.201412068.DC1.html Original image data can be found at: The Rockefeller University Press $30.00 http://jcb-dataviewer.rupress.org/jcb/browse/10902 J. Cell Biol. Vol. 210 No. 1 23–33 www.jcb.org/cgi/doi/10.1083/jcb.201412068 JCB 23 Published July 6, 2015 malian cells express six Prx isoforms (PrxI to PrxVI), which are with a retroviral vector encoding a modified form of catalase implicated in a variety of cellular processes. either with a centrosome-targeting pericentrin-AKAP450 cen- trosomal targeting (PACT) sequence (Cat-PACT) or with the corresponding sequence lacking the centrosome-targeting core Results and discussion (Cat-delPACT; Fig. 2 A; Gillingham and Munro, 2000). The presence of Cat-PACT and the absence of Cat-delPACT at the Phosphorylation of centrosome-associated centrosome were verified by confocal immunofluorescence mi- PrxI in early mitotic cells croscopy (Fig. 2 B). HeLa cells that had been infected with the Whereas high H2O2 levels induce cell cycle arrest, low H2O2 empty, Cat-PACT, or Cat-delPACT vectors were synchronized levels are required for G1–S and G2–M phase transitions (Ha- at G1–S by thymidine treatment and released in the presence vens et al., 2006; Yamaura et al., 2009). The molecular mech- of nocodazole for 10 h (Fig. 2 C). Early mitotic cells were anisms by which H2O2 modulates cell cycle progression have scored on the basis of cell rounding (Fig. 2 D) and chromosome remained unclear, however. To examine the possible link be- condensation (Fig. 2 E). The number of mitotic cells (mean of tween the role of H2O2 in cell cycle regulation and PrxI phos- values from Fig. 2, D and E) for cells expressing Cat-PACT 90 phorylation on Thr , we monitored this latter event during was reduced by ∼45% and ∼35% compared with that for cells the cell cycle in HeLa cells that had been synchronized at the infected with the empty vector or the vector encoding Cat-del- G1–S border (0 h) with a double thymidine block and then re- PACT, respectively. Immunoblot analysis of the infected HeLa leased for various times. Phosphorylated PrxI (pPrxI) appeared cells showed that the level of inactive (Tyr15 phosphorylated) slightly earlier than did the mitotic marker phosphorylated Cdk1 in Cat-PACT cells was about twice that in Cat-delPACT histone H3 (pHH3), and it disappeared in parallel with pHH3 cells and that the level of pHH3 in Cat-PACT cells was ∼50% of (Fig. 1 A). When HeLa or U2OS cells arrested in prometaphase that in Cat-delPACT cells (Fig. 2, F and G). Such analysis also with nocodazole were released from the arrest, pPrxI disap- revealed that Cat-PACT and Cat-delPACT were expressed sta- peared rapidly, with the rate of its loss being slightly greater bly at low levels relative to endogenous peroxisomal catalase, than that for cyclin B1 or pHH3 (Fig. S1 A). suggesting that any effect of Cat-PACT present in the cytosol Downloaded from The amount of pPrxI in prometaphase HeLa cells was es- instead of at the centrosome as a result of excessive expression timated to be ∼0.4% of total PrxI (Fig. S1 B). We therefore rea- was minimal (Fig. 2 F). We also monitored mitotic entry by soned that PrxI phosphorylation is likely a localized event, and fluorescence imaging of live cells after the release of Cat-PACT we searched for its location in asynchronously growing HeLa and Cat-delPACT cells from G1–S arrest. Mitotic entry of Cat- cells using confocal microscopy. pPrxI was found to colocalize PACT cells was delayed by a mean of ∼2–3 h compared with with the centrosome marker γ-tubulin at early stages of mitosis that of Cat-delPACT cells (Fig. 2 H; and Videos 1 and 2). These (prometaphase and metaphase) but not during interphase or late results thus supported the notion that exposure of the centro- on April 13, 2017 mitotic stages (anaphase, telophase, and cytokinesis; Fig. 1 B). some to H2O2 is required for normal mitotic entry. The centrosome is composed of a pair of centrioles surrounded We also found that the centrosomal levels of cyclin B1, by pericentriolar material. Structured illumination microscopy Plk1, and Aurora A in Cat-PACT cells were reduced by 55, 30, (SIM; Fig. 1 C) revealed that although pPrxI is colocalized with and 40%, respectively, compared with those in Cat-delPACT Cep192, a pericentriolar material marker of mitotic cells (Kim cells, suggesting that exposure of the centrosome to H2O2 is et al., 2013), there are also regions of Cep192 that do not ex- likely required to protect them from degradation (Fig.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Review Article PTEN Gene: a Model for Genetic Diseases in Dermatology
    The Scientific World Journal Volume 2012, Article ID 252457, 8 pages The cientificWorldJOURNAL doi:10.1100/2012/252457 Review Article PTEN Gene: A Model for Genetic Diseases in Dermatology Corrado Romano1 and Carmelo Schepis2 1 Unit of Pediatrics and Medical Genetics, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy 2 Unit of Dermatology, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy Correspondence should be addressed to Carmelo Schepis, [email protected] Received 19 October 2011; Accepted 4 January 2012 Academic Editors: G. Vecchio and H. Zitzelsberger Copyright © 2012 C. Romano and C. Schepis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. PTEN gene is considered one of the most mutated tumor suppressor genes in human cancer, and it’s likely to become the first one in the near future. Since 1997, its involvement in tumor suppression has smoothly increased, up to the current importance. Germline mutations of PTEN cause the PTEN hamartoma tumor syndrome (PHTS), which include the past-called Cowden, Bannayan- Riley-Ruvalcaba, Proteus, Proteus-like, and Lhermitte-Duclos syndromes. Somatic mutations of PTEN have been observed in glioblastoma, prostate cancer, and brest cancer cell lines, quoting only the first tissues where the involvement has been proven. The negative regulation of cell interactions with the extracellular matrix could be the way PTEN phosphatase acts as a tumor suppressor. PTEN gene plays an essential role in human development. A recent model sees PTEN function as a stepwise gradation, which can be impaired not only by heterozygous mutations and homozygous losses, but also by other molecular mechanisms, such as transcriptional regression, epigenetic silencing, regulation by microRNAs, posttranslational modification, and aberrant localization.
    [Show full text]
  • Bioinformatics-Based Screening of Key Genes for Transformation of Liver
    Jiang et al. J Transl Med (2020) 18:40 https://doi.org/10.1186/s12967-020-02229-8 Journal of Translational Medicine RESEARCH Open Access Bioinformatics-based screening of key genes for transformation of liver cirrhosis to hepatocellular carcinoma Chen Hao Jiang1,2, Xin Yuan1,2, Jiang Fen Li1,2, Yu Fang Xie1,2, An Zhi Zhang1,2, Xue Li Wang1,2, Lan Yang1,2, Chun Xia Liu1,2, Wei Hua Liang1,2, Li Juan Pang1,2, Hong Zou1,2, Xiao Bin Cui1,2, Xi Hua Shen1,2, Yan Qi1,2, Jin Fang Jiang1,2, Wen Yi Gu4, Feng Li1,2,3 and Jian Ming Hu1,2* Abstract Background: Hepatocellular carcinoma (HCC) is the most common type of liver tumour, and is closely related to liver cirrhosis. Previous studies have focussed on the pathogenesis of liver cirrhosis developing into HCC, but the molecular mechanism remains unclear. The aims of the present study were to identify key genes related to the transformation of cirrhosis into HCC, and explore the associated molecular mechanisms. Methods: GSE89377, GSE17548, GSE63898 and GSE54236 mRNA microarray datasets from Gene Expression Omni- bus (GEO) were analysed to obtain diferentially expressed genes (DEGs) between HCC and liver cirrhosis tissues, and network analysis of protein–protein interactions (PPIs) was carried out. String and Cytoscape were used to analyse modules and identify hub genes, Kaplan–Meier Plotter and Oncomine databases were used to explore relationships between hub genes and disease occurrence, development and prognosis of HCC, and the molecular mechanism of the main hub gene was probed using Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway analysis.
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • Lenalidomide Induces Cell Death in an MDS-Derived Cell Line with Deletion of Chromosome 5Q by Inhibition of Cytokinesis
    Leukemia (2010) 24, 748–755 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ORIGINAL ARTICLE Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis A Matsuoka1, A Tochigi1, M Kishimoto1, T Nakahara1, T Kondo1, T Tsujioka1, T Tasaka1, Y Tohyama2 and K Tohyama1 1Department of Laboratory Medicine, Kawasaki Medical School, Okayama, Japan; and 2Division of Biochemistry, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Hyogo, Japan Myelodysplastic syndromes (MDS) are a group of hematopoietic higher-risk groups with del(5q) that are susceptible to leukemic stem cell disorders characterized by refractory cytopenias transformation.6 Several hematopoiesis-related genes and tumor and susceptibility to leukemic transformation. On a subset of suppressor genes are located at 5q locus, and SPARC,7 MDS patients with deletion of the long arm of chromosome5 8 9 10 11 (del(5q)), lenalidomide exerts hematological and cytogenetic CTNNA1, EGR1, RPS14 and CDC25C are reported as effects, but the underlying pharmacological mechanisms are the candidate genes of MDS with del(5q) or 5q- syndrome. not fully understood. In this study, we have investigated the Lenalidomide, a derivative of thalidomide, is shown to in vitro effects of lenalidomide on an MDS-derived cell line, exert plenty of biological actions including inhibition of MDS-L, which carries del(5q) and complex chromosome angiogenesis,12 suppression of proinflammatory cytokine abnormalities. We found that the growth of MDS-L cells was production such as TNF-a,13 enhancement of T- and NK-cell specifically suppressed mainly by apoptosis, and in addition, 14–16 multinucleated cells were frequently formed and finally died activation.
    [Show full text]
  • Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1 by Dahlia Doughty Shenton Department of Biochemistry Duke
    Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1 by Dahlia Doughty Shenton Department of Biochemistry Duke University Date: May 1 st 2009 Approved: ___________________________ Dr. Patrick J. Casey, Supervisor ___________________________ Dr. Perry J. Blackshear ___________________________ Dr. Anthony R. Means ___________________________ Dr. Christopher B. Newgard ___________________________ Dr. John D. York Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Biochemistry in the Graduate School of Duke University 2009 ABSTRACT Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1 by Dahlia Doughty Shenton Department of Biochemistry Duke University Date: May 1 st 2009 Approved: ___________________________ Dr. Patrick J. Casey, Supervisor ___________________________ Dr. Perry J. Blackshear ___________________________ Dr. Anthony R. Means ___________________________ Dr. Christopher B. Newgard ___________________________ Dr. John D. York An abstract of a dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Biochemistry in the Graduate School of Duke University 2009 Copyright by Dahlia Doughty Shenton 2009 Abstract The dual specificity protein tyrosine phosphatases comprise the largest and most diverse group of protein tyrosine phosphatases and play integral roles in the regulation of cell signaling events. The dual specificity protein tyrosine phosphatases impact multiple
    [Show full text]
  • Identification of Seven Hub Genes As the Novel Biomarkers in Triple
    Identication of Seven Hub Genes as the Novel Biomarkers in Triple-negative Breast Cancer and Breast Cancer Metastasis Huanxian Wu Southern Medical University Huining Lian Southern Medical University Nanfang Hospital Qianqing Chen Southern Medical University Jinlamao Yang Southern Medical University Nanfang Hospital Baofang Ou Southern Medical University Dongling Quan Southern Medical University Lei Zhou Southern Medical University Lin Lv Southern Medical University Minfeng Liu Southern Medical University Nanfang Hospital Shaoyu Wu ( [email protected] ) Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, Guangdong, 510515, PR China. https://orcid.org/0000-0002- 1247-5295 Research article Keywords: Triple-negative breast cancer, Metastasis, Biomarkers, Prognostic signature Posted Date: October 5th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-73076/v1 Page 1/20 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/20 Abstract Background: Breast cancer is one of the most common malignant tumors with the highest morbidity and mortality among women. Compared with the other breast cancer subtypes, Triple-negative breast cancer (TNBC) has a higher probability of recurrence and is prone to distant metastasis. To reveal the underlying disease mechanisms and identify more effective biomarkers for TNBC and breast cancer metastasis. Methods: Gene Ontology and KEGG pathway analysis were used for investigating the role of overlapping differentially expressed genes (DEGs). Hub genes among these DEGs were determined by the protein- protein interactions network analysis and CytoHubba. Oncomine databases were used for verifying the clinical relevance of hub genes.
    [Show full text]
  • CDKN3 Mrna As a Biomarker for Survival and Therapeutic Target in Cervical Cancer
    RESEARCH ARTICLE CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer Eira Valeria Barrón1,2, Edgar Roman-Bassaure3, Ana Laura Sánchez-Sandoval4, Ana María Espinosa1, Mariano Guardado-Estrada1, Ingrid Medina1, Eligia Juárez1, Ana Alfaro1, Miriam Bermúdez1, Rubén Zamora5,6, Carlos García-Ruiz1, Juan Carlos Gomora4, Susana Kofman7, E. Martha Pérez-Armendariz2¤, Jaime Berumen1,2* 1 Unidad de Medicina Genómica, Facultad de Medicina, Universidad Nacional Autónoma de México/ Hospital General de México, México City, México, 2 Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México, 3 Servicio de Oncología, Hospital General de México, México City, México, 4 Departamento de Neuropatología Molecular, División de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, México City, México, 5 Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México City, México, 6 Laboratorio de Biología Molecular, Asociación para Evitar la Ceguera en México Hospital Dr. Luis Sánchez-Bulnes, México City, México, 7 Servicio de Genética, Hospital General de México/Facultad de Medicina, Universidad Nacional Autónoma de México, México City, México ¤ Current address: Departamento de Biología, Celular y Tisular, Facultad de Medicina, Universidad Nacional OPEN ACCESS Autónoma de México, México City, México * [email protected] Citation: Barrón EV, Roman-Bassaure E, Sánchez- Sandoval AL, Espinosa AM, Guardado-Estrada M, Medina I, et al. (2015) CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Abstract Cancer. PLoS ONE 10(9): e0137397. doi:10.1371/ CDKN3 journal.pone.0137397 The cyclin-dependent kinase inhibitor 3 ( ) gene, involved in mitosis, is upregulated in cervical cancer (CC).
    [Show full text]
  • PTEN Enhances G2/M Arrest in Etoposide-Treated MCF-7 Cells
    ONCOLOGY REPORTS 35: 2707-2714, 2016 PTEN enhances G2/M arrest in etoposide-treated MCF-7 cells through activation of the ATM pathway RUOPENG ZHANG1,2, LI ZHU2, LIRONG ZHANG2, ANLI XU2, ZHENGWEI LI3, YIJUAN XU3, PEI HE3, MAOQING WU4, FENGXIANG WEI5 and CHENHONG Wang1 1Department of Obstetrics and Gynecology, Shenzhen Maternity and Child Healthcare Hospital, Affiliated to Southern Medical University, Longgang, Shenzhen, Guangdong 518028; 2Department of Reproductive Medicine, Affiliated Hospital of Dali University, Dali, Yunnan 671000;3 Clinical Medicine College of Dali University, Dali, Yunnan 671000, P.R. China; 4Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; 5The Genetics Laboratory, Shenzhen Longgang District Maternity and Child Healthcare Hospital, Longgang, Shenzhen, Guangdong 518028, P.R. China Received November 19, 2015; Accepted December 27, 2015 DOI: 10.3892/or.2016.4674 Abstract. As an effective tumor suppressor, phosphatase and role in etoposide-induced G2/M arrest by facilitating the acti- tensin homolog (PTEN) has attracted the increased attention of vation of the ATM pathway, and PTEN was required for the scientists. Recent studies have shown that PTEN plays unique proper activation of checkpoints in response to DNA damage roles in the DNA damage response (DDR) and can interact in MCF-7 cells. with the Chk1 pathway. However, little is known about how PTEN contributes to DDR through the ATM-Chk2 pathway. It Introduction is well-known that etoposide induces G2/M arrest in a variety of cell lines, including MCF-7 cells. The DNA damage-induced Cellular DNA is constantly challenged by either endogenous G2/M arrest results from the activation of protein kinase [reactive oxygen species (ROS)] or exogenous (UV) factors.
    [Show full text]
  • A Novel Synthetic Inhibitor of CDC25 Phosphatases: BN82002
    [CANCER RESEARCH 64, 3320–3325, May 1, 2004] A Novel Synthetic Inhibitor of CDC25 Phosphatases: BN82002 Marie-Christine Brezak,1 Muriel Quaranta,2 Odile Monde´sert,2 Marie-Odile Galcera,1 Olivier Lavergne,1 Fre´de´ric Alby,2 Martine Cazales,2 Ve´ronique Baldin,2 Christophe Thurieau,1 Jeremiath Harnett,1 Christophe Lanco,1 Philip G. Kasprzyk,1,3 Gregoire P. Prevost,1 and Bernard Ducommun2 1IPSEN, Institut Henri Beaufour, Les Ulis Cedex, France; 2Laboratoire de Biologie Cellulaire et Moleculaire du Controle de la Proliferation-Centre National de la Recherche Scientifique UMR5088-IFR109 “Institut d’Exploration Fonctionnelle des Ge´nomes,” Universite´ Paul Sabatier, Toulouse, France; and 3IPSEN, Biomeasure, Milford, Massachusetts ABSTRACT B at mitosis (2) where it dephosphorylates tyrosine 15 and threonine 14. It also plays a role in the control of the initiation of S phase (5). CDC25 dual-specificity phosphatases are essential regulators that de- The elucidation of the specific role of each isoform at specific stages phosphorylate and activate cyclin-dependent kinase/cyclin complexes at of the cell cycle is a major issue that is still currently under investi- key transitions of the cell cycle. CDC25 activity is currently considered to be an interesting target for the development of new antiproliferative gation. agents. Here we report the identification of a new CDC25 inhibitor and Overexpression of CDC25A and B, but not C, has been observed in the characterization of its effects at the molecular and cellular levels, and a variety of cancers (i.e., breast, ovary, head and neck, and colon) with in animal models. a striking association with tumor aggressiveness and poor prognosis BN82002 inhibits the phosphatase activity of recombinant human (6–9).
    [Show full text]
  • Chromosome Position Previous Kreatech Name New Kreatech
    The Pathology Company Kreatech Probes assigned new names as per HUGO Naming Guidelines As part of our on-going commitment to customer service and communication, Kreatech probes are changing from their current product names to those published in the guidelines from the HUGO Gene Nomenclature Committee at the European Bioinformatics Institute. In the table below you will find all Kreatech probes, listed first by chromosome position, the previous Kreatech probe name and then the new name as per HUGO guidelines. For further details you can visit the HGNC database of human gene names: www.genenames.org Chromosome Position Previous Kreatech New Kreatech HUGO Name Name 1p36 CHD5 CHD5 1p34 MYCL MYCL 1q21 S100A10 S100A10 1q21 CKS1B CKS1B 1q32 MDM4 MDM4 2p24 MYCN, NMYC MYCN 2p23 ALK ALK 2p21 EML4 EML4 2q11 LAF AFF3 3p25 PPARy PPARG 3q26 hTERC TERC 3q26 EVI MECOM 3q27 BCL6 BCL6 4p16 FGFR3 FGFR3 4p16 WHSC1, MMSET WHSC1 4q12 FIP1L1 FIP1L1 4q12 CHIC2 CHIC2 4q12 PDGFRA PDGFRA 4q21-22 AFF1, MLLT2 AFF1 5p15 hTERT TERT 5p15 CTNND CTNND2 5q31 CDC25C CDC25C 5q31 EGR1 EGR1 The Pathology Company 5q33 PDGFRB PDGFRB 5q33 CSF1R CSF1R 5q33 RPS14 RPS14 5q35 NSD1 NSD1 5q35 FGFR4 FGFR4 6p25 DUSP22 DUSP22 6p25 IRF4 IRF4 6p24 RREB1 RREB1 6p23 MYB MYB 6p22 DEK DEK 6p21 CCND3 CCND3 6q21 SEC63 SEC63 6q22 ROS1 ROS1 6q27 MLLT4, AF6 MLLT4 7p11 EGFR, Her1 EGFR 7q11 ELN ELN 7q11 LIMK1 LIMK1 7q22 CUTL1 CUX1 7q31 C-MET MET 7q31 MDFIC MDFIC 8p23 GATA4 GATA4 8p21 PNOC PNOC 8p11 FGFR1 FGFR1 8q21 ETO RUNX1T 8q24 C-MYC MYC 9p24 JAK2 JAK2 9p21 MLLT3, AF9 MLLT3 9p21 p16 CDKN2A 9q34
    [Show full text]
  • Direct Roles of the Signaling Kinase RSK2 in Cdc25c Activation During Xenopus Oocyte Maturation
    Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation Ruoning Wanga,b,1, Sung Yun Jungc, Chuan Fen Wua, Jun Qinc, Ryuji Kobayashid, Gary E. Gallicke, and Jian Kuanga,b,2 Departments of aExperimental Therapeutics, dMolecular Pathology, and eGenitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030; bProgram in Genes and Development, University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030; and cDepartment of Biochemistry, Baylor College of Medicine, Houston, TX 77030 Edited* by John Gerhart, University of California, Berkeley, CA, and approved October 6, 2010 (received for review March 22, 2010) The induction of M phase in eukaryotic cell cycles requires robust phosphorylations catalyzed by such identified kinases “primary activation of Cdc2/cyclin B by Cdc25, which itself is robustly activated phosphorylations.” By fractionation of MEE, our previous results by serine/threonine phosphorylations. Although multiple protein demonstrated that 10–20% of the primary Cdc25C phosphory- kinases that directly activate Cdc25C have been identified, whether lating activity is due to Cdc2/cyclin B, which phosphorylates the combination of different primary phosphorylations of Cdc25C Cdc25C at the proline-directed sites T138, S285, and T308 and is sufficient to fully activate Cdc25C has not been determined. By activates GST-Cdc25C two- to fourfold. Approximately 40% of analyzing the GST-Cdc25C phosphorylating activity in Xenopus egg the activity is due to p42 MAPK, which phosphorylates Cdc25C at extracts, we previously defined roles of MAPK and Cdc2/cyclin B in the proline-directed sites T48, T138, and S205 and also activates partially activating Cdc25C and predicted the presence of another GST-Cdc25C two- to fourfold.
    [Show full text]